Refile-Perspective Therapeutics : Oppenheimer Adjusts Target Price to $19 From $2 to Reflect 1-for-10 Reverse Stock Split (Clarifies PT Is Split-Adjusted)
投資者:透視治療(Perspective Therapeutics):Oppenheimer將目標價從2美元上調至19美元,以反映1比10的股票拆分(澄清透視治療的目標價已經進行了股票拆分調整)